Siplizumab for Kidney Transplant Rejection

(MODERNIZE1 Trial)

This trial explores whether siplizumab, an experimental therapy, can prevent kidney transplant rejection in individuals with end-stage kidney disease. Participants will divide into three groups: two will receive different doses of siplizumab, and the third will receive rabbit anti-thymocyte globulin (rATG), an existing immunosuppressive drug. The trial aims to assess how well participants' bodies accept the transplanted kidney and compare the effects and safety of siplizumab to rATG. Individuals who recently received a kidney from a living or recently deceased donor and have no history of certain infections or major health issues may qualify for participation. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant advancements in kidney transplant care.

The trial does not specify if you need to stop your current medications, but you will continue taking the usual anti-rejection medicines given before, during, and after a kidney transplant.

Research has shown that siplizumab is generally safe for people. Studies have found that most individuals tolerate it well, with few serious side effects. In earlier research with kidney transplant patients, siplizumab was considered safe. Safety studies also revealed that siplizumab remains active in the body for a short time after administration, helping to control its effects.

Researchers are excited about siplizumab for kidney transplant rejection because it offers a novel approach to preventing rejection. Unlike the standard treatments, such as rabbit anti-thymocyte globulin, which broadly suppress the immune system, siplizumab specifically targets the CD2 receptor on T cells. This targeted action could mean fewer side effects and a more precise way to prevent the immune system from attacking the transplanted kidney. Additionally, by exploring both low and high doses of siplizumab, researchers hope to optimize its effectiveness and safety.

This trial will compare siplizumab with rabbit anti-thymocyte globulin to prevent kidney transplant rejection. Research has shown that siplizumab might be a promising option for this purpose. Studies have found that siplizumab is generally safe and may work well with other medications to prevent rejection. Its unique mechanism could make it more effective than some current treatments. Early results suggest it can reduce the activity of certain immune cells that might otherwise attack the new kidney. While more information is needed, these initial findings are encouraging for those considering siplizumab as a treatment option.¹²³⁵⁶